These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29226734)

  • 21. Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.
    Lattanzi M; Balar AV
    Curr Oncol Rep; 2019 Feb; 21(3):24. PubMed ID: 30806823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The emerging treatment landscape of advanced urothelial carcinoma.
    Cardenas L; Dibajnia P; Lalani AK
    Curr Opin Support Palliat Care; 2021 Dec; 15(4):247-252. PubMed ID: 34620772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent developments in the treatment of advanced bladder cancer.
    Godwin JL; Hoffman-Censits J; Plimack E
    Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Atezolizumab (Tecentriq
    Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
    Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma.
    Patel R; Bock M; Polotti CF; Elsamra S
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):225-232. PubMed ID: 28043166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.
    Tang G; Liu J; Qi L; Li Y
    Br J Clin Pharmacol; 2023 Jan; 89(1):93-113. PubMed ID: 35997657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
    Santini D; Banna GL; Buti S; Isella L; Stellato M; Roberto M; Iacovelli R
    Curr Oncol Rep; 2023 Nov; 25(11):1345-1362. PubMed ID: 37855848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
    Ortmann CA; Mazhar D
    Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
    Rassy E; Assi T; Kattan J
    Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
    [No Abstract]   [Full Text] [Related]  

  • 32. Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
    Szabados B; van Dijk N; Tang YZ; van der Heijden MS; Wimalasingham A; Gomez de Liano A; Chowdhury S; Hughes S; Rudman S; Linch M; Powles T
    Eur Urol; 2018 Feb; 73(2):149-152. PubMed ID: 28917596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in the management of urothelial carcinoma: is immunotherapy the answer?
    Santopietro AL; Einstein D; Bellmunt J
    Expert Opin Pharmacother; 2021 Sep; 22(13):1743-1759. PubMed ID: 33905290
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular biology and targeted therapies for urothelial carcinoma.
    Seront E; Machiels JP
    Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers for immunotherapy in bladder cancer: a moving target.
    Aggen DH; Drake CG
    J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
    Montazeri K; Sonpavde G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updates and novel treatments in urothelial carcinoma.
    Hanna KS
    J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors: a new frontier in bladder cancer.
    Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
    World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.